IGC News and Press, India Globalization Capital Inc. From 12/07/22

India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022. The legislation establishes a new registration process for conducting research on marijuana ...

POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was...

India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According ...

India Globalization Capital (NYSE American: IGC) has announced that its Chief Executive Officer Ram Mukunda will be presenting at the RHK Disruptive Growth Conference in New York City. Mukunda is slated to present beginning at 11:20 a.m. ET on Monday, Dec. 5, and will also be available for one-o...

Company To Host Conference Call on Friday, December 2 at 11 a.m. ET India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial...

POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Mond...

Summary Currently, several pharmaceutical companies are testing candidates’ drugs and some of them are in the final stages of trials. The huge revenue potential is at stake in this race for the best anti-agitation drug for dementia and Alzheimer's patients. BioXcel's BX...

India Globalization Capital Inc. (NYSE American: IGC) posted rising revenues and cut losses as it reported its second fiscal quarter 2023 financial results. Revenue was roughly $202,000 for the second quarter, versus $56,000 during the same time last year. The company said that th...

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC ba...

India Globalization Capital (NYSE American: IGC) is reporting financial results for second quarter 2023, the period ending Sept. 30, 2022. Highlights of the report include the potential shown by IGC-AD1 and TGR-63, the company’s main investigational drug assets, to suppress or ameli...